Alternate Day Fasting, Exercise, and NAFLD

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Illinois at Chicago
Study ID
NCT04004403
Status
Completed

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Obesity

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Alternate day fasting — OTHER
    The diet involves consuming 600 kcal on the "fast day" and eat ad libitum at home on alternating "feed days".
  • Exercise — OTHER
    The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.

Study Details

Approximately 65% of obese individuals have non-alcoholic fatty liver disease (NAFLD), and this condition is strongly related to the development of insulin resistance and diabetes. Innovative lifestyle strategies to treat NAFLD are critically needed. The proposed research will demonstrate that alternate day fasting (ADF) combined with exercise is an effective non-pharmacological therapy to treat NAFLD.

Key Dates

Start date
Sep 1, 2019
Status verified
Sep 2025
Primary completion
May 1, 2024
Completion
May 1, 2024

Study Design

Enrollment
80 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Alternate day fasting
    These participants will consume 600 kcal on the "fast day" and eat ad libitum at home on alternating "feed days".
  • Experimental: Exercise
    These participants will participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
  • Experimental: Combination alternate day fasting plus exercise
    These participants will consume 600 kcal on the "fast day" and eat ad libitum at home on alternating "feed days". They will also participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
  • No Intervention: Control
    Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits.

Primary Outcome Measure

Change in Hepatic Steatosis [ Time Frame: Change from week 1 to week 12 ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Illinois ChicagoChicagoIllinois60612-

Find similar trials in Chicago, IL

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
University of Illinois Chicago· Chicago, IL

Related Studies